Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1.

ABSTRACT:

SUBMITTER: Lukes J 

PROVIDER: S-EPMC7665249 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature